Last Posted: Feb 15, 2020
- MTHFR Gene and Folic Acid
CDC, February 2020 - Folic Acid Information
CDC, January 2020 - Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
Páez David et al. British journal of cancer 2019 120(2) 190-195 - Energy balance related lifestyle factors and risk of endometrial and colorectal cancer among individuals with lynch syndrome: a systematic review.
Coletta Adriana M et al. Familial cancer 2019 Jun - Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Oyaga-Iriarte Esther et al. Journal of pharmacological sciences 2019 May - Machine Learning Models for Genetic Risk Assessment of Infants with Non-syndromic Orofacial Cleft.
Zhang Shi-Jian et al. Genomics, proteomics & bioinformatics 2018 16(5) 354-364 - Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
Roncato R et al. Clinical pharmacology and therapeutics 2017 102(1) 123-130 - Genetic Literacy of pregnant women and their use of prenatal screening and diagnostic tests in Turkey.
Seven Memnun et al. Journal of genetic counseling 2019 Jan - 2019 Digital Toolkit: NATIONAL BIRTH DEFECTS PREVENTION MONTH
- The impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX.
Shirasu Hiromichi et al. Cancer science 2018 Nov
.png)
No hay comentarios:
Publicar un comentario